Arexvy RSV vaccine
Selected indexed studies
- The recent landscape of RSV vaccine research. (Ther Adv Vaccines Immunother, 2025) [PMID:39802673]
- Nirsevimab: A Review. (Pediatr Allergy Immunol Pulmonol, 2024) [PMID:38484270]
- In Brief: RSV vaccine (Arexvy) for ages 50-59. (Med Lett Drugs Ther, 2024) [PMID:39008103]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The recent landscape of RSV vaccine research. (2025) pubmed
- Nirsevimab: A Review. (2024) pubmed
- In Brief: RSV vaccine (Arexvy) for ages 50-59. (2024) pubmed
- Respiratory Syncytial Virus Infection: An Update. (2023) pubmed
- Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. (2023) pubmed
- Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia. (2025) pubmed
- Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus. (2024) pubmed
- Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. (2025) pubmed
- Arexvy: A Comprehensive Review of the Respiratory Syncytial Virus Vaccine for Revolutionary Protection. (2024) pubmed
- Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (2024) pubmed